Introduction
Throughout the history of the world, the ones who had confronted the bitterest face of poverty and war had always been the women. As known poverty and war affects human health either directly or indirectly, the effects of this condition on health and status of women in the society should not be ignored. This study intends to cast light on the effects of war and poverty on the reproductive health of women. For this purpose, the face of war affecting the women, the problem of immigration, inequalities in distribution of income based on gender and the effects of all these on the reproductive health of women will be addressed.
War and Women's Health
Famine, synonymous with war and poverty, is clearer for women; war means deep disadvantages such as full destruction, loss of future and uncertainty for women. Wars are conflicts that destroy families, societies and cultures that negatively affect the health of community and cause violation of human rights. According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1). War has many negative effects on human health. One of these is its effect of shortening the average human life. According to the data of WHO, the average human life is 68.1 years for males and 72.7 years for females. It is being thought that severe military conflicts in Africa shorten the expected lifetime for more than 2 years. In general, WHO had calculated that 269 thousand people had died in 1999 due to the effect of wars and that loss of 8.44 million healthy years of life had occurred (2, 3) . Wars negatively affect the provision of health services. Health institutions such as hospitals, laboratories and health centers are direct targets of war. Moreover, the wars cause the migration of qualified health employees, and thus the health services hitches. Assessments made indicate that the effect of destruction in the infrastructure of health continues for 5-10 years even after the finalization of conflicts (3) . Due to resource requirements in the restructuring investments after war, the share allocated to health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and children. While deaths depending on direct violence affect the male population, the indirect deaths kill children, women and elders more. In Iraq between 1990-1994, infant deaths had shown this reality in its more bare form with an increase of 600% (4). The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5) . As the result of wars and armed conflicts, women are
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Results
A total of 31 patients met the inclusion criteria and were included in the study. The mean age of the patients was 48.39 ± 3.9 years, (age range: 40-55 years). The significant characteristics of patients are summarized in Table 1 . The average duration of AUB was 1.64 ± 0.5 (age range: 1-3 years).
Nineteen patients (61.3%) had taken hormone therapy in a form of either oral contraceptive (OCP) or progesterone previously. The mean age of menarche was 12.59± 1.27 years. The average numbers for gravida, parity, and abortion were 3.6, 3.3, and 0.36, respectively. Most of the patients were illiterate (25.8%) or had primary education (51.6%) and lived in urban areas (64.5%). Only 29.1% of patients had background medical conditions such as hypertension, diabetes mellitus, or ovarian polycystic disease.
The significant histological changes in endometrium as an inactive or atrophic endometrium were observed in 24 (77.4%) patients after treatment with letrozole and metformin (P < 0.001).
The treatment was clinically effective in 18 (58.1%) cases as completely stopped bleeding and in 6 (19.4%) patients as decreased amount of bleeding. As shown in Table 2 , the treatment was not effective in 7 (22.6%) cases with a background of proliferative endometrium (P< 0.001).
The minor side effects in the patients receiving letrozole and metformin were: headache in 4 patients (12.5%), flushing in 6 patients (19.3%), and weight loss in 7 patients (22.5%), but no major side effects were seen.
Discussion
Many of epidemiologic and experimental studies have reported the role of unopposed estrogen in development of endometrial benign, premalignant, and malignant lesions and AUBs (21) (22) (23) (24) (25) . Disordered proliferative endometrium could be the first level of the estrogen-driven endometrial changes. Aromatase inhibitors, such as letrozole, may show a therapeutic effect at this stage by suppressing the peripheral conversion of androgens to estrogens. A study conducted by Gharabaghi et al compared the effect of letrozole with megestrol in the treatment of AUB due to disordered proliferative endometrium or simple hyperplasia. They concluded both medications similarly affected the selected patients. The histological response to letrozole was reported as atrophic endometrium in 58.7% and weakly proliferative endometrium in 34.78% of cases. Other studies carried out by Barker et al, Li et al, and Berstein et al on the cases of endometrial hyperplasia or adenocarcinoma revealed that letrozole was successful in decreasing endometrial thickness and stopping bleeding (27) (28) (29) . Moreover, the same results were reported from using anastrozole, another aromatase inhibitor, for treatment of hyperplastic endometrium (30) .
On the other hand, Tabrizi et al studied the antiestrogenic effect of metformin in the patients with AUB diagnosed with disordered proliferative or simple hyperplastic endometrium and showed good response in 95.5% of cases who took 1000 mg metformin daily for 3 months versus 61.9% response in megestrol group (31) .
Several studies confirmed that metformin could be used as an effective drug in the treatment of disordered proliferative endometrium (32, 33) . In the current study, to assess the effect of these two drugs together, for the first time, we aimed to evaluate the effect of letrozole and metformin on endometrial histology in the patients with disordered proliferative endometrium. Based on our results, significant clinical and histologic responses to the treatment with letrozole and metformin were observed in 77.5% and 77.4% of cases, respectively. This study demonstrated that combination of letrozole and metformin could be used as a new and effective therapy in the patients with disordered proliferative endometrium.
Conclusions
Treatment of disordered proliferative endometrium with letrozole and metformin is effective in most of the patients; however, the success of this therapeutic strategy should be reassessed in a randomized clinical trial.
